Trade BioXcel Therapeutics, Inc. - BTAI CFD

BioXcel Therapeutics, Inc. Company profile

About BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on drug development that utilizes artificial intelligence (AI) approaches to develop therapies in neuroscience and immuno-oncology. The Company's two advanced clinical development programs are BXCL501, an investigational, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine (Dex), for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment-naive to checkpoint inhibitors.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, BioXcel Therapeutics Inc revenues was not reported. Net loss increased 30% to $106.9M. Higher net loss reflects General and administrative increase from $24.3M to $54.2M (expense), Interest income decrease of 72% to $44K (income), Interest expense increase of 48% to $40K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.79 to -$4.05.